• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测接受胸腔置管术的恶性胸腔积液患者的生存率。

Predicting the survival in patients with malignant pleural effusion undergoing indwelling pleural catheter insertion.

作者信息

Akram Muhammad Junaid, Khalid Usman, Ashraf Mohammad Bilal, Bakar Muhammad Abu, Butt Faheem Mahmood, Khan Faheem

机构信息

Department of Internal Medicine, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan.

Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan.

出版信息

Ann Thorac Med. 2020 Oct-Dec;15(4):223-229. doi: 10.4103/atm.ATM_289_20. Epub 2020 Oct 10.

DOI:10.4103/atm.ATM_289_20
PMID:33381237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7720744/
Abstract

CONTEXT

Malignant pleural effusion (MPE) is a common comorbid condition in advanced malignancies with variable survival.

AIMS

The aim of this study was to predict the survival in patients with MPE undergoing indwelling pleural catheter (IPC) insertion.

SETTINGS AND DESIGN

This was a cross-sectional study conducted at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.

METHODS

One hundred and ten patients with MPE who underwent IPC insertion from January 2011 to December 2019 were reviewed. Kaplan-Meier method was used to determine the overall survival (OS) of the patient's cohort with respect to LENT score.

STATISTICAL ANALYSIS USED

The IBM SPSS version 20 was used for statistical analysis.

RESULTS

We retrospectively reviewed 110 patients who underwent IPC insertion for MPE, with a mean age of 49 ± 15 years. 76 (69.1%) patients were females, of which majority 59 (53.6%) had a primary diagnosis of breast cancer. The LENT score was used for risk stratification, and Kaplan-Meier survival curves were used to predict the OS. The proportion of patients with low-risk LENT score had 91%, 58%, and 29% survival, the moderate-risk group had 76%, 52%, and 14% survival, and in the high-risk group, 61%, 15%, and 0% patients survived at 1, 3, and 6 months, respectively. In addition, there was a statistically significant survival difference ( = 0.05) in patients who received chemotherapy pre- and post-IPC insertion.

CONCLUSIONS

LENT score seems to be an easy and attainable tool, capable of predicting the survival of the patients with MPE quite accurately. It can be helpful in palliating the symptoms of patients with advanced malignancies by modifying the treatment strategies.

摘要

背景

恶性胸腔积液(MPE)是晚期恶性肿瘤中常见的合并症,患者生存期各异。

目的

本研究旨在预测接受留置胸腔导管(IPC)插入术的MPE患者的生存期。

设置与设计

这是一项在巴基斯坦拉合尔的沙卡特汗姆纪念癌症医院及研究中心开展的横断面研究。

方法

回顾了2011年1月至2019年12月期间接受IPC插入术的110例MPE患者。采用Kaplan-Meier法确定患者队列相对于LENT评分的总生存期(OS)。

所用统计分析方法

使用IBM SPSS 20版进行统计分析。

结果

我们回顾性分析了110例因MPE接受IPC插入术的患者,平均年龄为49±15岁。76例(69.1%)为女性,其中大多数59例(53.6%)的原发诊断为乳腺癌。采用LENT评分进行风险分层,并使用Kaplan-Meier生存曲线预测OS。低风险LENT评分的患者在1个月、3个月和6个月时的生存率分别为91%、58%和29%,中度风险组分别为76%、52%和14%,高风险组分别为61%、15%和0%。此外,IPC插入术前和术后接受化疗的患者在生存方面存在统计学显著差异(P = 0.05)。

结论

LENT评分似乎是一种简单且可实现的工具,能够相当准确地预测MPE患者的生存期。它有助于通过调整治疗策略缓解晚期恶性肿瘤患者的症状。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9673/7720744/5b6884b4a8f6/ATM-15-223-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9673/7720744/7828d6c42f34/ATM-15-223-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9673/7720744/5b6884b4a8f6/ATM-15-223-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9673/7720744/7828d6c42f34/ATM-15-223-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9673/7720744/5b6884b4a8f6/ATM-15-223-g002.jpg

相似文献

1
Predicting the survival in patients with malignant pleural effusion undergoing indwelling pleural catheter insertion.预测接受胸腔置管术的恶性胸腔积液患者的生存率。
Ann Thorac Med. 2020 Oct-Dec;15(4):223-229. doi: 10.4103/atm.ATM_289_20. Epub 2020 Oct 10.
2
Validating LENT score in malignant pleural effusion.验证LENT评分在恶性胸腔积液中的应用
Future Sci OA. 2024 May 20;10(1):FSO958. doi: 10.2144/fsoa-2023-0168. eCollection 2024.
3
Indications and clinical outcomes of indwelling pleural catheter placement in patients with malignant pleural effusion in a cancer setting hospital.癌症治疗医院中留置胸腔导管在恶性胸腔积液患者中的适应证和临床结局。
Clin Respir J. 2020 Nov;14(11):1040-1049. doi: 10.1111/crj.13239. Epub 2020 Aug 28.
4
The Hospital and Patient Burden of Indwelling Pleural Catheters: A Retrospective Case Series of 210 Indwelling Pleural Catheter Insertions.留置胸腔导管的医院和患者负担:210 例留置胸腔导管插入术的回顾性病例系列。
Respiration. 2019;97(1):70-77. doi: 10.1159/000491934. Epub 2018 Sep 18.
5
Australasian Malignant PLeural Effusion (AMPLE)-4 trial: study protocol for a multi-centre randomised trial of topical antibiotics prophylaxis for infections of indwelling pleural catheters.澳大利亚恶性胸腔积液(AMPLE)-4 试验:一项多中心随机试验的研究方案,该试验旨在研究局部抗生素预防留置胸腔导管感染的效果。
Trials. 2024 Apr 10;25(1):249. doi: 10.1186/s13063-024-08065-1.
6
Use of indwelling pleural catheters for the definitive treatment of malignant pleural effusion.使用留置胸膜导管对恶性胸腔积液进行确定性治疗。
J Bras Pneumol. 2017 Jan-Feb;43(1):14-17. doi: 10.1590/S1806-37562016000000021. Epub 2017 Jan 23.
7
Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion.贝伐珠单抗通过留置胸腔导管治疗有症状的非小细胞肺癌恶性胸腔积液的疗效。
BMC Pulm Med. 2024 Feb 16;24(1):89. doi: 10.1186/s12890-024-02886-1.
8
An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore.一项观察性研究评估 LENT 评分在新加坡肺腺癌恶性胸腔积液选定人群中的表现。
Respiration. 2018;96(4):308-313. doi: 10.1159/000489315. Epub 2018 Jun 26.
9
Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.使用常规临床参数对合并恶性胸腔积液的恶性胸膜间皮瘤患者进行生存分层的预测模型。
Thorac Cancer. 2021 Dec;12(24):3304-3309. doi: 10.1111/1759-7714.14202. Epub 2021 Oct 26.
10
Safety of indwelling pleural catheter use in patients undergoing chemotherapy: a five-year retrospective evaluation.化疗患者使用留置胸膜导管的安全性:一项为期五年的回顾性评估。
BMC Pulm Med. 2016 Mar 11;16:41. doi: 10.1186/s12890-016-0203-7.

引用本文的文献

1
Management and prognosis of malignant pleural effusions managed with indwelling pleural catheters.采用留置胸膜导管治疗恶性胸腔积液的管理与预后
J Bras Pneumol. 2023 Dec 4;49(6):e20230225. doi: 10.36416/1806-3756/e20230225.
2
Malignant pleural effusion diagnosis and therapy.恶性胸腔积液的诊断与治疗。
Open Life Sci. 2023 Feb 28;18(1):20220575. doi: 10.1515/biol-2022-0575. eCollection 2023.
3
Outcome of Intermittent Thoracentesis versus Pigtail Catheter Drainage for Hepatic Hydrothorax.间歇性胸腔穿刺术与猪尾导管引流术治疗肝性胸腔积液的疗效比较

本文引用的文献

1
Indwelling pleural catheters for malignancy-associated pleural effusion: report on a single centre's ten years of experience.留置胸膜导管治疗恶性肿瘤相关性胸腔积液:单中心十年经验报告。
BMC Pulm Med. 2019 Dec 2;19(1):232. doi: 10.1186/s12890-019-1002-8.
2
Indwelling pleural catheters: an overview and real-life experience.留置胸膜导管:概述及真实临床经验。
QJM. 2019 Aug 1;112(8):599-604. doi: 10.1093/qjmed/hcz116.
3
ERS/EACTS statement on the management of malignant pleural effusions.ERS/EACTS 声明:恶性胸腔积液的处理。
J Clin Med. 2022 Dec 5;11(23):7221. doi: 10.3390/jcm11237221.
4
Management of Malignant Pleural Effusions in U.S. Veterans: A Retrospective Review.美国退伍军人恶性胸腔积液的管理:回顾性研究。
Ann Thorac Cardiovasc Surg. 2022 Dec 20;28(6):420-428. doi: 10.5761/atcs.oa.22-00124. Epub 2022 Nov 3.
5
Incidence of complications from indwelling pleural catheter for pleural effusion: A meta-analysis.留置胸腔导管治疗胸腔积液并发症的发生率:一项荟萃分析。
Clin Transl Sci. 2023 Jan;16(1):104-117. doi: 10.1111/cts.13430. Epub 2022 Oct 17.
6
The Treatment of Malignant Pleural Effusion With Permanent Indwelling Pleural Catheters.永久性留置胸膜导管治疗恶性胸腔积液。
Dtsch Arztebl Int. 2022 Sep 5;119(35-36):595-600. doi: 10.3238/arztebl.m2022.0229.
Eur J Cardiothorac Surg. 2019 Jan 1;55(1):116-132. doi: 10.1093/ejcts/ezy258.
4
Risk factors for pleural effusion recurrence in patients with malignancy.恶性肿瘤患者胸腔积液复发的危险因素。
Respirology. 2019 Jan;24(1):76-82. doi: 10.1111/resp.13362. Epub 2018 Jul 2.
5
An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore.一项观察性研究评估 LENT 评分在新加坡肺腺癌恶性胸腔积液选定人群中的表现。
Respiration. 2018;96(4):308-313. doi: 10.1159/000489315. Epub 2018 Jun 26.
6
Prognostic Factors of Malignant Pleural Effusion among Palliative Care Outpatients: A Retrospective Study.姑息治疗门诊患者恶性胸腔积液的预后因素:一项回顾性研究
Indian J Palliat Care. 2018 Apr-Jun;24(2):184-188. doi: 10.4103/IJPC.IJPC_183_17.
7
Diagnosis and management of malignant pleural effusions: state of the art in 2017.恶性胸腔积液的诊断与管理:2017年的最新进展
J Thorac Dis. 2017 Sep;9(Suppl 10):S1111-S1122. doi: 10.21037/jtd.2017.07.79.
8
Management of Benign Pleural Effusions Using Indwelling Pleural Catheters: A Systematic Review and Meta-analysis.使用留置胸膜导管治疗良性胸腔积液:一项系统评价和荟萃分析。
Chest. 2017 Mar;151(3):626-635. doi: 10.1016/j.chest.2016.10.052. Epub 2016 Nov 11.
9
Long-Term Survival, Quality of Life, and Quality-Adjusted Survival in Critically Ill Patients With Cancer.癌症重症患者的长期生存、生活质量和质量调整生存
Crit Care Med. 2016 Jul;44(7):1327-37. doi: 10.1097/CCM.0000000000001648.
10
Safety of indwelling pleural catheter use in patients undergoing chemotherapy: a five-year retrospective evaluation.化疗患者使用留置胸膜导管的安全性:一项为期五年的回顾性评估。
BMC Pulm Med. 2016 Mar 11;16:41. doi: 10.1186/s12890-016-0203-7.